New Delhi, July 15 -- The Nifty Pharma index has gained 14.53% year-to-date (YTD), significantly outperforming the Nifty 50, which has declined 7.87% over the same period. The sector's strong performance has been driven by improving earnings visibility, resilient growth in the domestic formulations business and a shift towards defensive sectors amid heightened market volatility, according to experts.

Pharmaceutical stocks have also benefited from new product launches, strong domestic execution, and steady margin expansion, making the sector a preferred choice for investors amid an uncertain macroeconomic environment.

In contrast, the Nifty 50 has lagged due to a combination of global and domestic headwinds. Escalating geopolitical tensi...